DG051 is primarily researched for its potential therapeutic applications in the treatment of inflammatory diseases. It is particularly studied for its role in inhibiting leukotriene A4 hydrolase (LTA4H), an enzyme involved in the production of pro-inflammatory mediators. By targeting this enzyme, DG051 may help reduce inflammation and alleviate symptoms associated with conditions such as atherosclerosis, rheumatoid arthritis, and other chronic inflammatory disorders. Its development is focused on providing a novel approach to managing inflammation with potentially fewer side effects compared to traditional anti-inflammatory drugs. Ongoing research aims to validate its efficacy and safety in clinical settings.